The results of the meta-analysis indicated that compared with placebo, PARP inhibitor maintenance therapy is associated with an increase in PFS, which is consistent with findings of previous studies investigating the efficacy of PARP inhibitors for platinum sensitive ovarian cancer [32–34]. This evidence concerns the gene PARP1 and ovarian cancer.